Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma

Status Terminated

Clinical Trial Summary

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with stage III-IV melanoma that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Vaccines made from peptides or antigens may help the body build an effective immune response to kill tumor cells.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and clinically appropriate dose of human heat shock protein (hsp)110-gp100 chaperone complex melanoma vaccine (recombinant hsp110-gp100 chaperone complex vaccine) to recommend a phase II dose in stage IIIB/C and stage IV metastatic melanoma patients. SECONDARY OBJECTIVES: I. To examine the effect of the recombinant human hsp110-gp100 chaperone complex vaccine on measurable clinical tumor. II. To determine gp100 and hsp110 specific cell mediated and humoral immune responses elicited by the chaperone complex vaccine. III. To determine the effect of dose and serial administration of the chaperone complex vaccine on cell mediated and humoral immune responses. IV. To quantify patient characteristics (human leukocyte antigen [HLA] subtype, immune cell function, etc.) that may correlate with immune response to the chaperone complex vaccine. OUTLINE: This is a dose-escalation study. Patients receive recombinant hsp110-gp100 chaperone complex vaccine intradermally (ID) on days 1, 15, and 43 in the absence of unacceptable toxicity. After completion of study treatment, patients are followed up for 6 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01744171
Study type	Interventional
Source	Roswell Park Cancer Institute
Contact
Status	Terminated
Phase	Phase 1
Start date	March 26, 2013
Completion date	June 11, 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02224781` - Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	Phase 3
Completed	`NCT02107755` - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT01886235` - Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery	N/A
Completed	`NCT00553306` - Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma	Phase 1/Phase 2
Completed	`NCT00121225` - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma	Phase 2
Completed	`NCT00019448` - Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT01961115` - Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	Phase 2
Completed	`NCT01748747` - Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery	Early Phase 1
Terminated	`NCT01316692` - Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma	Phase 2
Active, not recruiting	`NCT01120275` - Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma	Phase 2
Terminated	`NCT01166126` - Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV	Phase 2
Terminated	`NCT01217411` - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer	Phase 1
Completed	`NCT01037790` - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	Phase 2
Completed	`NCT00288041` - Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00072163` - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma	Phase 2
Completed	`NCT00074308` - Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers	Phase 1/Phase 2
Completed	`NCT01989559` - Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery	Phase 1
Completed	`NCT00026143` - Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma	Phase 2
Completed	`NCT00006243` - Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma	N/A
Active, not recruiting	`NCT04284774` - Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	Phase 2